{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T22:56:17Z","timestamp":1780440977235,"version":"3.54.1"},"reference-count":25,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1764,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1111\/j.1346-8138.2010.01067.x","type":"journal-article","created":{"date-parts":[[2010,11,2]],"date-time":"2010-11-02T20:28:10Z","timestamp":1288729690000},"page":"536-540","source":"Crossref","is-referenced-by-count":28,"title":["Effectiveness of 0.1% topical tacrolimus in adult and children patients with vitiligo"],"prefix":"10.1111","volume":"38","author":[{"given":"Montree","family":"UDOMPATAIKUL","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pairutch","family":"BOONSUPTHIP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rungthiwa","family":"SIRIWATTANAGATE","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,11,2]]},"reference":[{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB1|cit1","first-page":"617","volume-title":"Fitzpatrick\u2019s Dermatology in General Medicine","author":"Halder","year":"2008"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB2|cit2","first-page":"526","volume-title":"Dermatology, WebMD Scientific American Medicine","author":"Grimes","year":"2003"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2165\/00128071-200102030-00006","article-title":"Vitiligo: pathogenesis and treatment","volume":"2","author":"Njoo","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB4|cit4","first-page":"181","article-title":"Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo","volume":"1226","author":"Schallreuter","year":"1994","journal-title":"Biochem Biophys Acta"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.2340\/0001555574124128","article-title":"High frequency of thyroid dysfunction in patients with vitiligo","volume":"74","author":"Heged\u00fcs","year":"1994","journal-title":"Acta Derm Venereol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1365-2133.1985.tb02057.x","article-title":"Vitiligo in diabetes mellitus","volume":"113","author":"Gould","year":"1985","journal-title":"Br J Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1034\/j.1600-0749.2003.00023.x","article-title":"Evidence for an autoimmune pathogenesis of vitiligo","volume":"16","author":"Ongenae","year":"2003","journal-title":"Pigment Cell Res"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0923-1811(99)00029-8","article-title":"Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo","volume":"21","author":"Caixia","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1346-8138.1997.tb02292.x","article-title":"Relationship between levels of soluble interleukin-2 receptor and the types and activity of vitiligo","volume":"24","author":"Honda","year":"1997","journal-title":"J Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0923-1811(98)00070-X","article-title":"Serum concentration of the soluble interleukin-2 receptor in vitiligo patients","volume":"19","author":"Yeo","year":"1999","journal-title":"J Dermatol Sci"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1034\/j.1600-0749.2002.1o049.x","article-title":"New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions","volume":"15","author":"Moretti","year":"2002","journal-title":"Pigment Cell Res"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/archderm.134.12.1532","article-title":"Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature","volume":"134","author":"Njoo","year":"1998","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB13|cit13","first-page":"618","article-title":"The macrolide immunosuppressants in dermatology: mechanisms of action","volume":"12","author":"Marsland","year":"2002","journal-title":"Eur J Dermatol"},{"issue":"1 Pt 1","key":"10.1111\/j.1346-8138.2010.01067.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.jaad.2003.12.031","article-title":"Topical tacrolimus therapy for vitiligo: therapeutic response and skin messenger RNA expression of proinflammatory cytokines","volume":"51","author":"Grimes","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/j.1468-3083.2009.03138.x","article-title":"Response of vitiligo to once- vs. twice daily topical tacrolimus: a controlled prospective, randomized observer-blinded trial","volume":"23","author":"Radakovic","year":"2009","journal-title":"J Eur Acad Dermatol Venereal"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1365-4632.2009.03852.x","article-title":"Efficacy and safety of tacrolimus cream 0.1% in treatment of vitiligo","volume":"48","author":"Xu","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1067\/mjd.2002.126250","article-title":"Topical tacrolimus for repigmentation of vitiligo","volume":"47","author":"Grimes","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB18|cit18","first-page":"158","article-title":"Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series","volume":"71","author":"Tanghetti","year":"2003","journal-title":"Cutis"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jaad.2004.05.036","article-title":"Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases","volume":"51","author":"Silverberg","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2165\/00003495-200565040-00002","article-title":"New treatment modalities for vitiligo","volume":"66","author":"Kostovic","year":"2005","journal-title":"Drugs"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/j.1365-4362.1994.tb02860.x","article-title":"Melanocyte reservoir in vitiligo","volume":"33","author":"Arrunategui","year":"1994","journal-title":"Inst J Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/1523-1747.ep12506603","article-title":"Demonstration of tyrosinase in the vitiligo skin of human beings by a sensitive fluorimeteric method as well as by 14C(U)-I-tyrosine incorperation into melanin","volume":"78","author":"Husain","year":"1982","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/1523-1747.ep12514597","article-title":"PUVA-induced repigmentation of vitiligo scanning electron microscopy of hair follicles","volume":"74","author":"Ortonne","year":"1980","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/1523-1747.ep12480997","article-title":"Role of hair follicles in the repigmentation of vitiligo","volume":"97","author":"Cui","year":"1991","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1346-8138.2010.01067.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0190-9622(03)00786-2","article-title":"Clinical study of repigmentation patterns with different treatment modalities and their correlation with speed and stability of repigmentation in 352 vitiligonous patches","volume":"50","author":"Parsad","year":"2004","journal-title":"J Am Acad Dermatol"}],"container-title":["The Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1346-8138.2010.01067.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1346-8138.2010.01067.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,31]],"date-time":"2024-03-31T23:31:17Z","timestamp":1711927877000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1346-8138.2010.01067.x"}},"subtitle":["Topical tacrolimus for vitiligo"],"short-title":[],"issued":{"date-parts":[[2010,11,2]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1346-8138.2010.01067.x","relation":{},"ISSN":["0385-2407"],"issn-type":[{"value":"0385-2407","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,2]]}}}